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Abstract
The tools for predictingclinical outcomeafter radiotherapyare not yet optimal. To improveon this,weapplied theCOXEN informatics
approach to in vitro radiation sensitivity data of transcriptionally profiled human cells and gene expression data from untreated head
and neck squamous cell carcinoma (HNSCC) and bladder tumors to generate a multigene predictive model that is independent of
histologic findings and reports on tumor radiosensitivity. The predictive ability of this 41-gene model was evaluated in patients with
HNSCC and was found to stratify clinical outcome after radiotherapy. In contrast, this model was not useful in stratifying similar
patients not treated with radiation. This led us to hypothesize that expression of some of the 41 genes contributes to tumor radio-
resistance and clinical recurrence. Hence, we evaluated the expression the 41 genes as a function of in vitro radioresistance in the
NCI-60 cancer cell line panel and found cyclophilin B (PPIB), a peptidylprolyl isomerase and target of cyclosporine A (CsA), had the
strongest direct correlation. Functional inhibition of PPIB by small interfering RNAdepletion or CsA treatment leads to radiosensitiza-
tion in cancer cells and reduced cellular DNA repair. Immunohistochemical evaluation of PPIB expression in patients with HNSCC
was found to be associated with outcome after radiotherapy. This work demonstrates that a novel 41-gene expression model of
radiation sensitivity developed in bladder cancer cell lines and human skin fibroblasts predicts clinical outcome after radiotherapy in
head and neck cancer patients and identifies PPIB as a potential target for clinical radiosensitization.
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Introduction
Radiation therapy is an important treatment modality for head and
neck and bladder cancer, either alone or in combination with chemo-
therapy [1,2]. However, the individual response to radiotherapy can
be variable, and hence, any tool that would predict response to this
modality would allow enhanced patient stratification among the vari-
ous treatment options [3]. In addition, once optimally selected, phar-
macologic approaches toward radiosensitization promise to further
enhance the benefit these patients derive from such treatment [4]. Cur-
rently, clinical characteristics of the patient and tumor are primarily
used to determine whether treatment with radiotherapy is appropriate
[5–7], whereas tumor imaging [8,9] and expression of genes in the
tumor tissue [10–12] have been proposed to possibly enhance this.
However, even when used together, these are not yet highly predictive
of radiation sensitivity of patient tumors before treatment.
Made possible by the development of gene expression microarray or
multiplex polymerase chain reaction technologies, mathematical models
involving expression measurements of multiple genes have been devel-
oped to serve as prognostic indicators of disease aggressiveness or patient
survival and to predict response to specific chemotherapeutic agents or
regimens [13,14]. Associations of tumor gene expression to radiation re-
sponse have been developed for cell lines [15–17] and for specific tumors
such as cervical cancer [18], breast cancer [19], colorectal adenocarcinoma
[20], and cancers of the head and neck [21,22]. In addition, a radiosen-
sitivity signature as an indicator of concurrent chemoradiation therapeutic
response has been tested in small sets of rectal, esophageal, and head and
neck cancers [17]. Although exciting, the predictive value of these models
across different histologic tumor types requires validation on larger and
more diverse sample sets. In addition, none have identified genes that
are both biomarkers and potential targets for radiosensitization.
Here, we hypothesize that merging three sources of data, namely
in vitro radiation sensitivity of cell lines, baseline gene expression of
these cell lines, and gene expression of human tumors from multiple
cancer histologies would provide a gene profile associated with clinical
outcome after radiotherapy as well as potentially identify those genes
that may be targets for radiosensitization. This approach would also be
less susceptible to identifying tumor histology-specific processes while
being more likely to identify broadly relevant targets to enhance the
effectiveness of radiotherapy.
Given successful chemosensitivity prediction of human cancer based
on in vitro drug sensitivity of cell lines, the Coexpression Extrapolation
(COXEN) informatics method [23–25] seemed uniquely suited to test
the hypothesis above. We applied this tool on the triumvirate sources of
data mentioned above to develop a multigene predictive model. This
model was tested for its ability to predict outcome in patients with head
and neck squamous cell carcinoma (HNSCC) treated with radiotherapy.
In vitro depletion studies of several genes in the model demonstrated that
some of these are both clinical response biomarkers and determinants
of cellular radiation sensitivity. Furthermore, we demonstrate that
pharmacologic inhibition of one such gene, cyclophilin B (PPIB), leads
to decreased DNA repair in cancer cells after irradiation. In summary,
our approach has provided both biomarkers of clinical outcome after
radiotherapy and potential therapeutic targets for radiosensitization.
Materials and Methods
Patient and Cell Line Data Sets
The patient and cell line data sets used in this study and their spe-
cific roles are listed in Tables W1A–W1B and in the Supplementary
Methods. Use of human tissue samples here was approved by the
University of Virginia institutional review board.
Development of the Radiation Response Prediction
Gene Expression Model
As Table W1A indicates, gene expression data sets were available on
different microarray platforms. To generate a prediction gene expres-
sion model (GEM) across all platforms, gene array data processing and
calibration were carried out as described in the Supplementary Meth-
ods. We used COXEN [23,25] to develop a model predictive of radi-
ation response. Figure W1A shows a schematic depiction of the
methodology. We used the BLA-40 bladder cancer cell line data set
(Table W1A) to discover genes differentially expressed according to
radiosensitivity. To determine the subset of these genes whose expres-
sion is relevant to human primary tumors, we determined which of
these shared similar patterns of coexpression with the human bladder
tumor sample data set (Smith et al. in Table W1A). For each of the
remaining probe sets, we measured the significance of differential ex-
pression between the 17 most radiosensitive (SF2 range = 0.19-0.51;
mean = 0.39) and the 10 most radioresistant (SF2 range = 0.72-0.98;
mean = 0.86) cell lines using Student’s t test. These numbers were
chosen to maximize the number of genes differentially expressed as a
function of intrinsic sensitivity to radiation as measured by SF2. We
selected the 300 most significantly differentially expressed probe sets
as candidate biomarkers for radiation response prediction.
We used a linear discriminant analysis (LDA) approach [26,27] to
develop the optimal gene model predictors of radiation response from
the 300 probes above as described in Supplementary Methods. To
select a GEM that effectively predicts radiation response of several can-
cer types, we tested the performance of candidate GEMs at predicting
radiation sensitivity within the Brock cell panel (Table W1B), as mea-
sured by the correlation between predicted sensitivities and actual
SF2 values. Candidate GEMs were iteratively constructed from the
300 candidate probe sets above, starting with a model consisting
of the top three candidate biomarkers and then successively adding
biomarkers until all candidate biomarkers were used. GEMs that re-
sulted in a higher magnitude of correlation between predicted and
actual sensitivity were more accurate at response prediction. We
selected a GEM that had the highest correlation with the smallest
number of probes.
Evaluation of the Radiation Response Prediction GEM
in Patient Data Sets
After using the human skin fibroblast (HSFs) cell line data set
(Brock) to guide the selection of the optimal GEM, we evaluated
the predictive ability of this model on two independent patient tumor
expression data sets (Figure W1B). We generated predictions for the
HNSCC patient data sets (Table W1A), such that each patient re-
ceived a GEM score reflective of the relative probability of response
to radiation therapy. Importantly, because data sets did not contain
information on tumor response (i.e., reduction in tumor size or stage,
etc) after radiotherapy, we used overall survival and event-free survival
(future distant metastasis) as defined in Rickman et al. (Oncogene.
2008;27:6607–6622) as surrogates of radiocurability. The implicit
limitations of this assumption are discussed below.
To assess the accuracy of the GEMprediction, we generated receiver
operating characteristic (ROC) curves for the 73 patients treated with
radiation for the Rickman HNSCC data set. To determine whether
our prediction model correctly classifies true responders as predicted
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responders without available response information, we made the
assumption that patients surviving more than 3 years without evidence
of disease were more likely to have responded to treatment than pa-
tients who died of disease. Hence, for the purposes of this ROC analy-
sis, we considered patients surviving more than 3 years without
evidence of disease to be “true responders” and patients who died of
disease as “true nonresponders.” From this ROC curve, we selected a
threshold GEM score value that yielded optimal sensitivity and specific-
ity, to dichotomize patients into predicted responders and predicted non-
responders in subsequent Kaplan-Meier analysis. We used the χ2 test to
determine the significance of the separation of Kaplan-Meier survival
curves between predicted responders and nonresponders.
To determine the utility of the GEM in relation to other clinical
variables in predicting patient outcome, we used Cox proportional
hazards regression model analysis to assess the significance of these
variables and continuous GEM scores. Because the number of patients
in the HNSCC test set studies (Table W1A) was relatively small
compared with the number of potentially predictive variables, we used
a stepwise AIC-based model selection technique to selectively remove
insignificant variables [27,28]. This technique leads to a more parsi-
monious model yet retains explanatory power [27,28].
PPIB and p16 Immunohistochemistry
For the Virginia HNSCC patient data set, 4-μm histologic sections
were cut, and PPIB and p16 immunohistochemistry (IHC) were carried
out as described in the SupplementaryMethods. Immunohistochemical
staining for cyclophilin was scored for the intensity of cytoplasmic stain-
ing (0 = absent, 1 = weak, 2 =moderate, 3 = strong), and for the purpose
of analysis, the scores were dichotomized into two groups: weak to ab-
sent (0-1) versus moderate to strong (2-3) expression. p16 IHC expres-
sion was scored as positive or negative for use in Kaplan-Meier analysis,
using the criteria devised by Reimers et al. [29].
Miscellaneous Procedures
All other procedures used in this article can be found in the Sup-
plementary Methods section.
Figure 1. Selection of the optimal 41-probe model GEM. (A) A plot of the prediction performance of candidate GEMs used to guide selec-
tion of optimal GEM. For each candidate GEM, we calculated the correlation between the GEM scores and the actual survival fractions for
the human fibroblast data set.We plot the correlation test P value for eachmodel versus the number of genes in themodel. Themodel with
41 genes balances prediction performance and parsimony. (B) Normalized survival fraction values and GEMscores on the HSF data set are
plotted in a bar plot. The Spearman rank–based correlation betweennormalizedGEMscore and survival fraction is−0.434,with a one-sided
P= .0465. Standardization of SF2 and COXENGEMscore involved reciprocal evaluation because higher SF2 indicated radioresistance and
higher COXEN GEM score was indicative of radiosensitivity. (C) Evaluation of the predictive ability of the 41-probe GEM in patients
with HNSCC. Kaplan-Meier curves for the HNSCC cancer patients stratified into predicted responders and predicted nonresponders.
Kaplan-Meier curves for patients only treated with radiation (n=72). The left panel shows the overall survival time, whereas the right panel
shows the progression-free survival time.
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Results
Development of a GEM Predictive of Cellular
Response to Radiation
A schematic of model generation and validation process is depicted
in Figure W1. Radiosensitivity data for both the bladder cancer
(BLA-40, Table W1A) and primary HSFs developed from skin biop-
sies collected from areas outside the radiation field in patients un-
dergoing radiotherapy (Brock, Table W1A), in the form of SF2 are
shown in TablesW2A andW2B, respectively. Of the 8470 Affymetrix
HG-U133A probe sets that had matching Illumina probes, we found
that 7515 probe sets survived the COXEN coexpression step between
bladder cell lines and human tumors. The 300 probe sets most differ-
entially expressed between the 17most radiosensitive (SF2 range = 0.19-
0.51; mean = 0.39) and 10most radioresistant (SF2 range = 0.72-0.98;
mean = 0.86) cell lines were chosen as candidate biomarkers for inclu-
sion in the radiation response GEM.We then assessed how well GEMs,
constructed reiteratively from these candidate biomarkers as described in
methods, were able to predict radiation sensitivity in the HSF cell line
panel and selected a 41-probeset model (TableW3) that was best able to
predict radiosensitivity in this panel (Figure 1A). A comparison of
the predicted and true radiosensitivity data for the HSF panel using
the 41-gene GEM is shown in Figure 1B.
Utility of the 41-Gene GEM in Stratifying Clinical Outcome
of Patients Treated with Radiotherapy
We next used the 41-gene GEM to predict the clinical response of
patients with HNSCC enrolled in independent clinical studies. The
Rickman HNSCC patient data set (Tables W1A and W1B) comprised
81 patients, of whom 73 were treated using radiotherapy alone, whereas
8 patients were treated with an unspecified chemotherapeutic regimen
in addition to radiotherapy. Because chemotherapy may have a signifi-
cant influence on patient response and because the subset of patients
treated with radiotherapy alone was sufficiently large, we restricted
our prediction assessment analysis to these 73 patients. Each patient
was first assigned a GEM score indicating the predicted relative proba-
bility of response to radiation. To assess prediction performance, we
generated an ROC curve that had a Wilcoxon rank-sum test P =
.015, indicating that the predictor was significantly better than random,
and an area under the curve (AUC) of 0.61. This ROC curve was used
to select a GEM score threshold value that allowed stratification of this
group into predicted responders and predicted nonresponders. Kaplan-
Meier analysis revealed significant separation in survival time between
the predicted responders and nonresponders in overall and progression-
free survival (Figure 1C).
Because in addition to radiation response, other patient and tumor
characteristics influence patient survival, we used Cox proportional
hazards regression model to determine the contribution of the GEM
response scores in addition to these other characteristics. All patients
with complete clinical information (72/73) and all available covariates
were included in this analysis with the stepwise AIC model selection
discarding the variables least significant to the end point. Results shown
in Table W4A (for overall survival) and Table W4B (for progression-
free survival) indicate the GEM score is a significant variable predicting
the overall survival hazard rate (P = .047). Table W4B shows that no
variable relates to progression-free survival hazard rate, but the GEM
score has the lowest P value (P = .068). We also sought to determine
whether two recently published predictive models of radiation response
in patients could predict outcome in our data sets [17,19]. Importantly,
neither model predicted clinical outcome in the Rickman data set
(Supplementary Results).
Supporting the notion that the 41-gene GEM informs about clin-
ical outcome after radiation and not general tumor aggressiveness
in bladder or HNSCC cancer is the finding that only 4 of 41 genes
are associated with stage, grade, invasive ability, or clinical outcome in
independently profiled cancer data sets found in Oncomine (Figure 2).
Together, these two analyses suggest the 41-gene GEM informs about
clinical outcome after radiation rather than a general reflection of
tumor aggressiveness.
Characteristics and Network Analysis of the 41 Genes
in the GEM
The genes corresponding to the probes in the 41-gene model were
identified, and gene ontology (GO) information was obtained from
the PANTHER database (Supplementary Results and Figure W2).
We then used the Ingenuity Pathways Analysis program to determine
whether genes in the model are found in a common network and, if so,
discover biomolecules that are known interactors with the latter. Inter-
estingly, unsupervised analysis revealed the top scoring network com-
prised 39 of the 41 genes of the GEM (Figure 3). In this network, the
39 genes of the radiation response model were found to interact with
genes such as KRAS, HRAS, MYC, MYCN, ABL1, ERBB2, PIK3R1,
P38MAPK,NFκB, and ERK that are known to be involved in radiation
Figure 2. Association of gene expression with stage, grade, and
outcome in bladder and head and neck cancer (HNSCC). Box plots
showing the association of 4 genes of the 41-gene GEM (TableW3)
that were found to be significantly associated with tumor stage,
grade, or clinical outcome in bladder and head and neck cancer
databases found in Oncomine. P values for the specific comparison
and tumor parameter used are indicated in the figure. The data sets
that contained these significant associations have been previously
published [50–56].
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response. These findings suggested that genes in the model might also
have causal roles in radioresistance.
PPIB and Acidic Ribosomal Phosphoprotein P1
and Response to Radiosensitivity In Vitro
To determine which of the 39 genes in this network have causal
roles in radioresistance, we identified those whose expression was most
strongly and directly related with this phenotype in a third cell panel,
the NCI-60 [16] (Table W1A). The top 2 genes with the strongest
correlation of expression to radioresistance were PPIB, and acidic ribo-
somal phosphoprotein P1 (RPLP1; FigureW3). Given this finding, we
sought to evaluate whether the expression of these genes regulated this
phenotype. Use of small interfering RNA (siRNA) provided depletion
of both proteins in UMUC-13d bladder cancer cells (Figure 4A).
Reduced levels of PPIB and RPLP1 were associated with reduction
in cell number after depletion (Figure 4A), and this was due to en-
hanced apoptosis (Figure 4B). When six human cancer cell lines were
transiently depleted of either PPIB or RPLP1 and irradiated, we noted
that cells with reduced levels of either PPIB or RPLP1 had reduced
clonogenicity (Figure 4C ). Because cyclophilins are bound and
inhibited by cyclosporine A (CsA), we sought to evaluate whether
CsA recapitulated the observed reduction in cell number observed with
PPIB depletion, we carried out a dose response in UMUC-13d bladder
cancer cells. Figure 5A indicates CsA can diminish overall cell numbers
during a 48-hour period compared with vehicle-treated cells, yet this
effect occurs only with doses greater than 8 μM. Interestingly, tran-
sient depletion of either PPIB or RPLP1 with and without CsA in
UMUC-13d cells indicated that only depletion of RPLP1 with CsA
addition results in enhanced apoptosis compared with all other experi-
mental groups, suggesting functional equivalence of PPIB and CsA
about this phenotype (Figure 5B). We next examined the effect of
PPIB depletion with and without CsA addition on the in vitro clono-
genic ability of UMUC-13d cells after exposure to radiation and found
that PPIB depletion or CsA had similar effects, whereas PPIB depletion
combined with CsA did not result in further reduction in clonogenic
potential (Figure 5C ). Finally, our data reveal that both PPIB deple-
tion and CsA inhibit DNA repair, and their combined use does not
reduce this further, suggesting that these act on the same pathway(s)
Figure 3. Network analysis of the 41-gene GEM. Ingenuity Pathways Analysis network containing 39 of the 41 genes in the radiation
response prediction GEM and functionally related genes. Symbols colored in blue represent the genes in the 41-gene GEM, whereas red
and uncolored symbols represent genes with known direct or indirect functional interactions with the GEM genes. Symbols colored in
red represent genes known to be associated with radiation.
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Figure 4. Effect of PPIB and RPLP1 depletion on in vitro growth and radiosensitivity in human cancer cell lines. (A) In vitro cell number
evaluation using alamarBlue (Invitrogen) assay after depletion of GL2 (control), PPIB or RPLP1 through siRNA in duplicate samples of
UMUC-13d bladder cancer cells. Inset: Western blot analysis after siRNA depletion of PPIB and RPLP1 as described in Supplementary
Methods. Antibodies against PPIB (clone k2e2; Santa Cruz Biotechnology) and RPLP1 (polyclonal; Sigma) were used. (B) Apoptosis was
assessed by the Annexin V–FITC Apoptosis Detection Kit I (BD Biosciences) per the manufacturer’s instructions 48 hours after trans-
fection with the siRNA duplexes for PPIB and RPLP1. Insets show FACS output. (C) Clonogenic survival in human cancer cell lines after
radiation at indicated dose and depletion of GL2 (control), PPIB, or RPLP1 through siRNA. *P < .05 (ANOVA) at the 8-Gy dose.
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regulating DNA repair (Figure 5D). This result mirrors the findings
on clonogenicity (Figure 5C ).
Association of PPIB Protein Expression with Patient
Outcome after Radiation
Given that PPIB RNA expression was strongly correlated to radio-
resistance (Figure W3), we evaluated the role of PPIB protein expres-
sion as a predictor of clinical outcome after radiation treatment of
patients with HNSCC at the University of Virginia (Table W1A).
PPIB protein levels were found to predict of clinical outcome in these
patients (Figure 6, A and B). Interestingly, expression of CDKN2A
(p16), a cyclin-dependent kinase inhibitor and surrogate marker of
human papillomavirus (HPV) infection, was recently found to predict
radiation response in patients with HNSCC [30]. Because this gene
was part of the signaling network associated with our 41-gene GEM
(Figure 3 and Table W3), we sought to determine whether its level of
protein expression provided additional predictive ability when com-
bined with that of PPIB. IHC evaluation revealed that p16 levels pro-
vided significant stratification of patients with high PPIB IHC
(Figure 6,C andD) levels supporting relevance of the 39-gene network
in radiosensitivity of human cancer.
Discussion
We developed a multigene predictor of clinical outcome after radiation
therapy that is applicable across several cancer types. Whereas other
predictors have been described to predict response to radiation, they
are based on clinical characteristics, single biomarkers, or panels designed
specifically for one cancer type. Our model uses genes concordantly
Figure 5. Effect of PPIB depletion and CsA on in vitro growth and radiosensitivity and DNA repair of human bladder cancer cells. (A) In vitro
cell number evaluation using alamarBlue (Invitrogen) assay after the addition of CsA at indicated doses to duplicate samples of UMUC-13d
bladder cancer cells. Arrow indicates dose used in panels B to D. (B) Apoptosis was assessed by the Annexin V–FITC Apoptosis Detection
Kit I (BD Biosciences) per themanufacturer’s instructions 48 hours after transfectionwith the siRNA duplexes for PPIB and RPLP1with and
without 8 μMCsA. Inset axis labels are similar to those in Figure 4B. (C) Clonogenic survival in UMUC-13d bladder cancer cells after radiation
at the indicated dose and depletion of GL2 (control), PPIB through siRNA with and without 8 μM CsA. *P < .05 (ANOVA) at the 8-Gy dose.
(D) Comet assay carried out as described in Materials and Methods after transfection with the siRNA duplex for PPIB. Dose of CsA
was 8 μM. Each assay was normalized to cloning efficiency given the apoptosis induced by siRNA depletion. Indicated P values generated
using Student’s t test. The extent of DNA damage was measured 1 hour after a 10-Gy exposure.
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regulated between bladder cancer cell lines and human bladder can-
cer patients as previously successfully done for chemotherapy re-
sponse prediction [23,24]. Interestingly, this model provided
additional predictive ability even in patients who had other concom-
itant and potentially confounding treatments such as chemotherapy
treatment yet, importantly, did not offer any predictive ability in
patients who were not treated with radiation. This last observation
is similar to a recent breast cancer model [19] and suggests the exis-
tence of genomic classifiers that can separately predict prognosis or
therapy response.
Providing functional credibility to the model, we note that some
genes in the model are implicated in radiation response. The induction
of HRAS is associated with radiation resistance [31], and MYC acts
synergistically with HRAS to induce resistance [32]. p38 is involved
in regulating cellular responses to stress including stress induced by
ionizing radiation [33]. It is reassuring that NFκB transcription factor
is centrally represented in our network. This factor is involved in mul-
tiple cellular processes [34], and its constitutive activation has been
described in many cancer types and supports cancer cell survival and
to reduce the sensitivity against both radiation and chemotherapeutic
drugs [35–38].
We identified PPIB, a peptidylprolyl isomerase (PPIase), as a gene
and protein that is strongly related to both in vitro radiation response
and is a predictor of clinical outcome in patients with HNSCC. The
cyclophilins are members of a larger class of PPIase proteins widely ex-
pressed throughout the body, known as the immunophilins—targets
for the immunosuppressive agents FK506, CsA, and rapamycin
[39,40]. PPIB as a secreted protein is also thought to serve as a ligand
for the CD147 receptor, thereby regulating the motility of cells expres-
sing this receptor [41]. A recent study also indicates that PPIB present
in the conditioned medium of the MDA-MB-231 breast carcinoma
cell line promoted chemotaxis of bone marrow–derived mesenchymal
stromal cells [42]. Here we noted that depletion of PPIB protein en-
hanced cell killing after radiation likely by enhancing the apoptotic
process, the latter phenocopied by exposure of cancer cells to CsA
which binds PPIB. In addition to an enhanced level of apoptosis as
Figure 6. PPIB and CDKN2A (p16) expression in HNSCC. PPIB and p16 IHC and their relevance to outcome in HNSCC tumors treated
at the University of Virginia (n = 72). (A) Examples of the IHC scoring of PPIB. Each panel represents a tissue core in a tissue microarray;
the numbers 0 to 3 indicate the expression score given to the tumor in the specimen. Lymphocytes (L) present and infiltrating around
the tumor (T) also express this protein at high levels and serve as “internal controls” of staining intensity. (B) Kaplan-Meier curves of
overall survival of patients as a function of PPIB IHC score. (C) Examples of the IHC scoring of p16. Each panel represents a tissue core in
a tissue microarray; the characters (+) and (−) indicate the expression score (positive or negative, respectively), given to the tumor in the
specimen. (D) Kaplan-Meier curves of overall survival of PPIB-positive patients as a function of p16 IHC score.
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described here for CsA exposure or PPIB knockdown, there may also
be a role for DNA repair through PPIB knockdown. CsA binds and
inhibits PPIB, thus interfering with DNA repair [43,44] by decreasing
calcineurin-mediated expression of DNA polymerase β [45,46]. Using
a dominant negative form of polymerase β after ionizing radiation,
cell cycle position–dependent radiosensitization, higher numbers of
chromatid-type aberrations that result in replication-dependent sec-
ondary DNA double-strand breaks, and a higher number of chromo-
somal deletions were all seen [47–49], and the chromosomal deletions
were described as the mechanism of enhanced cell killing. Also sup-
porting the notion of reduced DNA repair capacity are the results from
the comet assay that measures both single- and double-strand breaks.
The induction of single-strand breaks occurs at a frequency of almost
two orders of magnitude over double-strand breaks and is ordinarily
rapidly repaired. Within 1 hour, more than 90% of the total strand
breaks would be repaired as seen in Figure 5C . Although it is residual
DNA lesions that drive cell death, given the extent of apoptosis seen
at 24 hours after irradiation, it is conceivable that unrepaired DNA
lesions, stalled replication forks, and others, may initiate the apoptotic
process in cells compromised by exposure to CsA or reduced PPIB
and RPLP1.
Our work has several limitations. Despite the fact that we used all
the suitable publicly available data sets of patients treated with radia-
tion to evaluate our model, the number of patients in there is relatively
small. In addition, because we did not have data on primary tumor
response, we were obliged to make the assumption that progression-
free and overall survival are radiocurability surrogates. While we realize
that lack of progression at the primary tumor site can be associated with
distant failure unrelated to the effect of radiation on the primary, we
posit that, given that our biomarker model predicted outcome only in
patients treated with radiation, whereas not in those who did not have
radiation, the model likely captures the elements of radiation response
in this albeit limited clinical scenario.
In summary, this work provides a novel approach for the discovery
of biomarkers that predict clinical outcome after radiation therapy
across multiple tumor histologic types. It also identifies PPIB as both
a biomarker of outcome after radiation therapy and a potential drug-
gable target for improving the effects of this modality. Despite limita-
tions because of the limited data sets used, these findings provide an
approach and framework that may improve treatment selection by dis-
covering markers that identify patients who can benefit most for func-
tional organ-sparing approaches with radiotherapy and, once selected,
offer these individuals even better outcomes by enhancing their
response to this treatment.
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Supplementary Methods
Patient Data Sets
As part of a study to develop predictors of metastasis among
HNSCC patients, 81 tumor samples were transcriptionally profiled
on Affymetrix HG-U133 Plus 2.0 GeneChips, and this information
is publicly available on ArrayExpress (www.ebi.ac.uk/arrayexpress
accession number E-TABM-302) [1,2]. The clinical characteristics
of the patients in this data set are summarized in Table W1A. Impor-
tantly, 73 of these patients were treated only with radiation therapy.
Additional validation was carried out on a set composed of 118 pa-
tients with HNSCC treated between 2002 and 2008 at the University
of Virginia with definitive radiation therapy alone or in combination
with induction and/or concurrent chemotherapy regimens. Patients
with T1-T2 primary tumors and N0-1 nodal disease were treated with
radiation alone and patients with T3-4 primary tumors or N2-3 nodal
disease received radiation and chemotherapy. Archived pretreatment
primary tumor biopsies were available for 72 patients and were used
to create a tissue microarray. Survival was calculated from the date of
diagnosis to the date of death of any cause or last date of follow-up. The
clinical characteristics of the patients in this data set are published [3].
Cell Line Data Sets
The data sets used in this study are listed in TablesW1A–W1B. The
bladder cancer cell line data set was used to select biomarkers and train
the prediction model. The gene expression profiles of unirradiated
samples of these cell lines have previously been measured using
Affymetrix HG-U133A GeneChips [4]. We used a human bladder
tumor sample data set to find genes concordantly regulated in these
bladder cell lines and human tumors. This data set consisted of 60 ex-
pression profiles downloaded from the Gene Expression Omnibus
(GEO) Web site (GEO Accession Number GSE3167) [5,6], as well
as 25 profiles obtained locally [7]. The gene expression profile and ra-
diation sensitivity of a panel of 16 primary HSF cell lines developed
from skin biopsies (Brock) from radiotherapy patients (collected from
areas outside the radiation field) was used to test prediction results de-
rived from the bladder cell lines to refine model selection. These 16 cell
lines were hybridized to Illumina WholeGenome6 v2 and v3 chips.
Samples of these cell lines were exposed to a total absorbed dose of 2 Gy
of ionizing radiation, after which the survival fraction was measured.
Gene Array Data Processing
Affymetrix data sets were background adjusted, quantile normal-
ized, and summarized using the Robust Multichip Average technique
[8-10]. Illumina data were processed according to the manufacturer.
As Tables W1A–W1B indicate, gene expression profiles were mea-
sured using several different microarray platforms. To generate a con-
sistent prediction model that could be applied to any of these data sets,
we limited subsequent analyses to genes that were present on all plat-
forms. First, because all 22215 Affymetrix HG-U133A probe sets are
also represented among the 54613 probe sets present on the Affymetrix
HG-U133 Plus 2.0 chip, we kept the expression values for this subset
in the head and neck human tumor data set and discarded the rest.
Second, because the head and neck cell line data set was profiled using
two versions of the Illumina WholeGenome6 chip, we used a file
downloaded from the Illumina Web site (illumina.com) to map iden-
tical or closely matching probes between the two versions. Most of the
cell lines in this experiment were profiled using version 2 of the WG6
chip, which has 48,701 probes. The cell lines C42, S34, and S38
were profiled using version 3, which has 48,803 probes. There are
43,071 probes that are identical or closely matching in the two ver-
sions. Affymetrix probe sets were mapped to Illumina probes using a
file downloaded from the IlluminaWeb site (illumina.com), which in-
dicated the probe sets and probes that corresponded to the same
RefSeq identifier. With these matching steps completed, 8406 unique
Illumina probes corresponded to 8470 unique Affymetrix Probe Sets.
GO and Network Analysis
To explore the functional properties of the genes in the radiotherapy
response prediction GEM, we found the gene information corre-
sponding to the probe sets from the NetAffx Web site. We queried
the PANTHER Classification System database at pantherdb.org for
GO information corresponding to the genes in the model [11,12].
We used the Ingenuity Pathways Analysis program (Ingenuity Systems,
www.ingenuity.com) to generate networks that include genes in the
radiation responseGEM.We also searched theOncomine database [13]
Table W1A. Patient and Cell Line Data Sets Used in Current Study.
Data Set Role and Name Disease State Total (N ) Radiation Only (n) Profiling Type Reference
Training Sets
BLA-40 Bladder cancer cell lines 40 39 Affymetrix HG-U133A [1]
Smith Bladder tumor patient samples 85 0 Affymetrix HG-U133A [2,3]
Model Optimization Set
Brock Primary HSFs from radiotherapy patients 16 16 Illumina WG6 Expression BeadChip Current article
Test Sets
NCI-60 60 human cancer lines 60 60 [4]
Rickman HNSCC patient samples 81 73 Affymetrix HG-U133 Plus 2.0 [5]
Virginia HNSCC patient samples 72 35 IHC for cyclophilin B and p16 Current article
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to determine which genes from the radiation response GEM were asso-
ciated with tumor stage, grade, and outcome in bladder and HNSCC.
Linear Discriminant Analysis
We used an LDA approach [14,15] to develop the optimal gene
model predictors of radiation response from the 300 probes above.
In general, for any given GEM that consists of a list of probe sets,
we train a linear discriminant using the expression values of the probe
sets in the model for the radiation-sensitive and radiation-resistant
bladder cancer cell lines. We apply this discriminant on the expression
values of an “optimization” cell line or patient data set to classify the
sample as a responder or a nonresponder. Each sample receives a GEM
score, which represents the posterior probability that the sample is
sensitive to radiation.
PPIB and p16 IHC
For the Virginia HNSCC patient data set, 4-μm histologic sections
were cut, placed on charged glass slides (SuperFrost Plus; Fisher Scien-
tific, Pittsburgh, PA), deparaffinized in xylene, and rehydrated in a
graded series of ethanol baths. The sections were immersed in target
retrieval solution, citrate pH 6.0 (Dako, Glostrup, Denmark), and
antigen retrieval was performed in a Pascal pressure chamber (Dako),
achieving 22 psi pressure for 30 seconds at 125°C. IHCwas performed
on a robotic platform (Autostainer; Dako). Endogenous peroxidases were
blocked using peroxidase and alkaline phosphatase blocking reagent
(Dako). Polyclonal rabbit antibody to PPIB (catalog no. Ab16045;
Abcam) was diluted 1:400, andmousemonoclonal antibody to p16 (cat-
alog no. 550834; BD Pharmingen, San Diego, CA) was diluted to 1:100
and applied at ambient temperature for 30 minutes. Antibody binding
was visualized by incubation with Envision Dual Link (Dako) followed
by incubation with 3,3′-diaminobenzidine tetrahydrochloride. Immuno-
histochemical staining for PPIB was scored for the intensity of cytoplas-
mic staining (0 = absent, 1 = weak, 2 = moderate, 3 = strong). p16 status
was determined by IHC as specified by Reimers et al. [16]. Tumors were
considered positive for p16 when strong nuclear and cytoplasmic
staining was present in more than 60% of cells [16].
Cell Line Irradiation, Clonogenic Survival Assay, and
Estimation of Radiosensitivity and DNA Repair
Thirty-nine bladder cancer cell lines from a previously described
panel of 40 (BLA-40 [4]) were cultured and irradiated with a total dose
of 2 Gy, and the fraction surviving was determined (SF2) as described.
In a similar fashion, using a panel of 16 primary HSF cell lines devel-
oped from skin biopsies (Brock) from radiotherapy patients (collected
from areas outside the radiation field), survival curves were generated
and SF2 was calculated from those curves using a linear quadratic fit
(α/β). Preradiation RNA from these 16 HSF cell lines was hybridized
to Illumina WholeGenome6 v2 and v3 chips.
Exponentially growing cells were transfected with siRNA and/or
treated with CsA as described in figures legends. After the treatments,
cells were irradiated at ambient temperature with 2 and 6 Gy of x-ray
(250 keV) and replated into 100-mm-diameter culture dishes at den-
sities calculated to yield 50 to 100 cell colonies per dish. After 10 to
14 days of incubation, cells were fixed and stained with crystal violet in
20% ethanol, and colonies more than 50 cells were counted. The
number of surviving colonies divided by the number of plated cells
was used to calculate the plating efficiency and survival fraction for
each treatment.
Analysis of DNA Damage Repair by the Comet Assay
Analysis of DNA damage repair by the comet assay was carried out
as described [17]. We used the standard comet assay (Trevigen,
Gaithersburg, MD) to compare the differences in DNA damage repair
between wild-type and siRNA knockdown cells. Briefly, exponentially
growing cells were irradiated (x-ray, 10 Gy) and allowed to recover for
1 hour. Cells were harvested, mixed with low-melting agarose, and
applied to comet slides. After lysis and alkaline unwinding, the electro-
phoresis was performed under alkaline (pH > 13) denaturating condi-
tions at 1 V/cm for 30 minutes. Slides were stained with SYBR green
dye for 10 minutes. One hundred randomly selected cells per sample
were captured under a fluorescent microscope and analyzed. The rel-
ative length and intensity of SYBR green–stained DNA tails to heads
were proportional to the amount of DNA damage present in the indi-
vidual nuclei and weremeasured by theOlive tail moment [17]. Cyclo-
sporine was purchased from Sigma (St Louis, MO) and used in vitro
as described [18].
In Vitro Cell Growth
Bladder cancer cells were seeded in 96-well cell culture plates at a
density of 5000 per well in a volume of 200 μl. Twenty-four hours
Table W1B. Rickman HNSCC Patient Characteristics [1] (Percentages May Not Add Up to 100
Because of Rounding).
All (n = 81) No Chemotherapy (n = 73)* Chemotherapy (n = 8)
Median age (years) 59 (35-79) 58 (35-79) 60 (43-71)
Sex, n (%)
Male 76 (94%) 68 (93%) 8 (100%)
Female 5 (6%) 5 (7%) 0
Pathologic T stage, n (%)
T1 3 (4%) 3 (4%) 0
T2 38 (47%) 32 (44%) 6 (75%)
T3 30 (37%) 29 (40%) 1 (12.5%)
T4 10 (12%) 9 (12%) 1 (12.5%)
Pathologic N stage, n (%)
N0 17 (21%) 17 (23%) 0
N1 15 (19%) 15 (21%) 0
N2a 1 (1%) 0 1 (12.5%)
N2b 26 (32%) 24 (33%) 2 (25%)
N2c 14 (17%) 12 (16%) 2 (25%)
N3 8 (10%) 5 (7%) 3 (37.5%)
Pathologic stage, n (%)
2 7 (9%) 7 (10%) 0
3 23 (28%) 20 (27%) 3 (37.5%)
4 51 (63%) 46 (63%) 5 (62.5%)
Grade, n (%)
1 19 (23%) 18 (25%) 1 (12.5%)
2 38 (47%) 33 (45%) 5 (62.5%)
3 24 (30%) 22 (30%) 2 (25%)
HPV status
HPV-free 75 (93%) 67 (92%) 8 (100%)
Undetermined 6 (7%) 6 (8%) 0
Localization, n (%)
Lip 18 (22%) 16 (22%) 2 (25%)
Mouth 10 (12%) 10 (14%) 0
Oropharynx 17 (21%) 16 (22%) 1 (12.5%)
Pharynx 36 (44%) 31 (42%) 5 (62.5%)
Overall survival
Alive, n (%) 29 (36%) 28 (38%) 1 (12.5%)
Dead, n (%) 50 (62%) 44 (60%) 6 (75%)
Unknown, n (%) 2 (2%) 1 (1%) 1 (12.5%)
Median (months) 55 (7-158) 59 (7-158) 36 (16-151)
Metastasis-free survival
Metastatic, n (%) 40 (49%) 34 (47%) 7 (87.5%)
Nonmetastatic, n (%) 41 (51%) 39 (53%) 1 (12.5%)
Median (months) 37 (3-158) 43 (3-158) 19 (5-151)
*Only 72 of the 73 had complete data.
later, the cells were transfected with the siRNA duplexes described
previously (6.25 nM) using Oligofectamine according to the manu-
facturer’s instructions in triplicate. Twenty-four hours later, the cells
were treated either with indicated concentrations of CsA or with
equal volumes of carrier (100% ethanol) in triplicate. Plates were in-
cubated for 24 to 48 hours with carrier or drug. The cell numbers
were assessed by alamarBlue (Invitrogen, Carlsbad, CA) per the
manufacturer’s instructions.
Apoptosis Assay
Bladder cancer cells were seeded in six-well cell culture plates at a
density of 83,000 per well in a volume of 2 ml. Twenty-four hours
later, the cells were transfected with the siRNA duplexes described pre-
viously (6.25 nM) using Oligofectamine (Invitrogen) according to the
manufacturer’s instructions. Apoptosis was assessed by the Annexin
V–FITC Apoptosis Detection Kit I (BD Biosciences, Franklin Lakes,
NJ) per the manufacturer’s instructions.
Small Interfering RNA
The following siRNA duplexes were chemically synthesized,
deprotected, and annealed by Dharmacon (Lafayette, CO): PPIB
siRNA duplex: 5′-GGUGGAGAGCACCAAGACA-3′ was described
[19]; Red Fluorescent Protein Ctrl siRNA duplex: 5′-(DY547)AAUU-
CUCCGAACGUGUCACGU-3′ served as a transfection efficiency
control and as a negative control. Luciferase (GL2) siRNA duplex:
5′-CGUACGCGGAAUACUUCGA-3′ served as a negative control.
Ribosomal protein, large, P1 (RPLP1) siRNA duplex was chem-
ically synthesized, deprotected and annealed by Sigma-Proligo (cat-
alog no. SASI_Hs01_00160252). Bladder cancer cells were grown at
50% confluence in 100-mmplates, and six-well plates were transfected
with the siRNA duplexes (6.25 nM) using Oligofectamine (Invitrogen)
according to the manufacturer’s instructions.
Western Blot Analysis
Western blot analysis was performed as detailed previously [20].
Antibodies against PPIB (clone k2e2; Santa Cruz Biotechnology,
Inc, Santa Cruz, CA) and RPLP1 (polyclonal; Sigma) were used. Im-
munoblots were developed using Super Signal Femto Chemilumines-
cence (Pierce, Rockford, IL), and results were visualized and quantified
using the Alpha Innotech (San Leandro, CA) imaging system. Mono-
clonal anti–α-tubulin (clone AA13; Santa Cruz Biotechnology, Inc)
Figure W1. Schematic diagram of gene expression model (GEM) development and validation. (A) GEM Development. Depiction of the
model selection process. The 955 probe sets not concordantly regulated between the bladder cancer cell line and human bladder cancer
patient data sets were first removed from consideration. Then the 300 genes most significantly differentially expressed between radiosen-
sitive and radioresistant bladder cancer cell lines were selected as candidate biomarkers. Models were constructed from these biomarkers,
trained on the bladder cancer cell line data set, and used to predict the sensitivity of 16 primary HSFs from patients treated with curative
intent with radiation. These prediction results were assessed by measuring the correlation between the GEM score and survival fraction for
the HNSCC lines. The optimal model was found to have 41 probes, and a graph of GEM score versus survival fraction is shown in Figure 2A.
(B) GEM validation. The optimal model was then used to predict the response to radiation for HNSCC cancer patient set (Table W1A).
was used to detect tubulin expression for normalization of expression
of PPIB or RPLP1.
Data Sets Searched for Associations of 41-Gene GEM
and Tumor Parameters and Clinical Outcome (Figure 2)
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Table W2A. Survival Fraction Values after 2 Gy of Ionizing Radiation (SF2) of Human Bladder
Cancer (BLA-40, Tables W1A–W1C).
Bladder Cell Line Mean Survival Fraction SD
253J-BV 0.461 0.061
253JLaval 0.506 0.035
253J-P 0.462 0.083
575A 0.481 0.017
BC16.1 0.500 0.046
CRL2169 0.948 0.065
CRL2742 0.657 0.033
CRL7193 0.506 0.106
CUBIII 0.721 0.041
EJ 0.341 0.051
FL3 0.974 0.023
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HTB9 0.603 0.022
HU456 0.376 0.004
J82 0.524 0.041
JON 0.297 0.047
KK47 0.768 0.072
KU7 0.515 0.036
MGH-U3 0.486 0.049
MGH-U4 0.597 0.067
PSI 0.494 0.082
RT4 0.800 0.035
SCaBER 0.603 0.100
SLT4 0.468 0.064
SW1710 0.588 0.076
T24 0.626 0.089
T24T 0.319 0.055
TCCSUP 0.198 0.021
UMUC1 0.846 0.069
UMUC13D 0.973 0.026
UMUC14 0.778 0.029
UMUC2 0.523 0.052
UMUC3 0.969 0.031
UMUC3-E 0.460 0.025
UMUC6 0.360 0.041
UMUC9 0.633 0.110
VMCUB1 0.398 0.036
VMCUB2 0.870 0.085
VMCUB3 0.509 0.063
Table W2B. Survival Fraction Values after Absorbing 2 Gy of Ionizing Radiation of Primary HSF
Cell Lines Developed from Skin Biopsies (Brock, Tables W1A–W1C).
HNSCC Cell Line Survival Fraction
C28 0.300
C29 0.330
C34 0.288
C38 0.339
C39 0.361
C42 0.167
C43 0.423
C56 0.194
C66 0.333
C68 0.302
C69 0.303
C74 0.175
C80 0.410
S10 0.437
S34 0.140
S38 0.131
Table W3. The 41 Genes Corresponding to Probe Sets in the Optimal GEM of Cellular Response to Radiation.
Gene Symbol Probe ID Gene Name Molecular Function Biological Process
ACADVL 200710_at ILMN_1806408 Acyl-coenzyme A dehydrogenase, very long chain Dehydrogenase Acyl-CoA metabolism; electron transport
AP3M2 203410_at ILMN_1676946 Adaptor-related protein complex 3, mu 2 subunit Other membrane traffic protein Pinocytosis; transport
ATP5F1 211755_s_at ILMN_1721989 ATP synthase, H+ transporting,
mitochondrial F0 complex, subunit B1
Hydrogen transporter; synthase;
other hydrolase
Cation transport
BLK 206255_at ILMN_1668277 B lymphoid tyrosine kinase Non–receptor tyrosine protein kinase Carbohydrate transport; protein phosphorylation;
intracellular signaling cascade; transport;
immunity and defense; embryogenesis;
neurogenesis; mesoderm development;
cell cycle control; cell proliferation
and differentiation; oncogene
C17orf62 218130_at ILMN_1750401 Chromosome 17 open reading frame 62 Molecular function unclassified Biologic process unclassified
C19orf66 53720_at ILMN_1750400 Hypothetical protein FLJ11286 Molecular function unclassified Biologic process unclassified
CCDC76 219130_at ILMN_1659786 coiled-coil domain containing 76 Molecular function unclassified Biologic process unclassified
CFLAR 211317_s_at ILMN_1789830 CASP8 and FADD-like apoptosis regulator Cysteine protease Proteolysis; apoptosis
CLNS1A 209143_s_at ILMN_1736814 Chloride channel, nucleotide-sensitive, 1A Other transporter Anion transport
CLPX 204809_at ILMN_1709894 ClpX caseinolytic peptidase X homolog (E. coli) Other chaperones Protein folding; proteolysis; transport
CREB3 209432_s_at ILMN_1703072 cAMP-responsive element binding protein 3 CREB transcription factor;
nucleic acid binding
mRNA transcription regulation
DNM3 209839_at ILMN_1680928 Dynamin 3 Microtubule family cytoskeletal protein;
small GTPase; other hydrolase
Endocytosis; transport; cell structure
GPRC5A 203108_at ILMN_1682599 G protein–coupled receptor, family C,
group 5, member A
Molecular function unclassified Biologic process unclassified
IL15 205992_s_at ILMN_1724181 Interleukin 15 Interleukin Cytokine and chemokine–mediated
signaling pathway; MAPKKK cascade;
JAK-STAT cascade; ligand-mediated
signaling; immunity and defense;
inhibition of apoptosis
INVS 210114_at ILMN_1763137 Inversin Molecular function unclassified Proteolysis; cell surface receptor–mediated
signal transduction
IRAK4 219618_at ILMN_1692352 Interleukin-1 receptor-associated kinase 4 Serine/threonine protein kinase receptor;
non–receptor serine/threonine
protein kinase
Protein phosphorylation; receptor
protein serine/threonine kinase signaling
pathway; immunity and defense
LBA1 213261_at ILMN_1750321 Lupus brain antigen 1 Molecular function unclassified Biologic process unclassified
MIS12 221559_s_at ILMN_1718069 MIS12, MIND kinetochore complex component,
homolog (yeast)
Molecular function unclassified Biologic process unclassified
MRPL13 218049_s_at ILMN_1671158 Mitochondrial ribosomal protein L13 Ribosomal protein Protein biosynthesis
NFKBIE 203927_at ILMN_1717313 Nuclear factor of kappa light polypeptide gene
enhancer in B-cell inhibitor, epsilon
Molecular function unclassified Biologic process unclassified
NOS3 205581_s_at ILMN_1775224 Nitric oxide synthase 3 (endothelial cell) Synthase; oxidoreductase;
calmodulin-related protein
Electron transport; nitric oxide biosynthesis;
NO-mediated signal transduction;
other metabolism
OLA1 219293_s_at ILMN_1659820 GTP-binding protein 9 (putative) G protein Biologic process unclassified
PALM 203859_s_at ILMN_1812031 Paralemmin Other miscellaneous function protein Signal transduction
PBLD 219543_at ILMN_1713319 Phenazine biosynthesis-like protein
domain containing
Oxidoreductase Other metabolism
PPIB 200967_at ILMN_1711745 Peptidylprolyl isomerase B (cyclophilin B) Other isomerase Protein folding; nuclear transport;
immunity and defense
PRRG1 205618_at ILMN_1781791 Proline-rich Gla (G-carboxyglutamic acid) 1 Molecular function unclassified Biologic process unclassified
PSMB9 204279_at ILMN_1798233 Proteasome (prosome, macropain) subunit,
beta type, 9 (large multifunctional peptidase 2)
Other proteases Proteolysis
PSMG2 218467_at ILMN_1797445 Tumor necrosis factor superfamily,
member 5–induced protein 1
Other nucleic acid binding Other apoptosis; induction of apoptosis;
other developmental process
RNF115 212742_at ILMN_1811997 Zinc finger protein 364 Molecular function unclassified Biologic process unclassified
RPL8 200936_at ILMN_1764721 Ribosomal protein L8 Other RNA-binding protein;
ribosomal protein
Protein biosynthesis
RPLP1 200763_s_at ILMN_1689725 Ribosomal protein, large, P1 Ribosomal protein Protein biosynthesis
SEPT7 213151_s_at ILMN_1729019 Septin 7 Cytoskeletal protein; small GTPase Cytokinesis
SETD3 212465_at ILMN_1724504 SET domain containing 3 Molecular function unclassified Biologic process unclassified
STAT4 206118_at ILMN_1785202 Signal transducer and activator
of transcription 4
Other transcription factor;
nucleic acid binding
Biologic process unclassified
TGDS 208249_s_at ILMN_1685567 TDP-glucose 4,6-dehydratase Dehydratase; epimerase/racemase Glycogen metabolism
TMEM135 222209_s_at ILMN_1700202 Transmembrane protein 135 Molecular function unclassified Biologic process unclassified
TMEM70 219448_at ILMN_1739032 Transmembrane protein 70 Molecular function unclassified Biologic process unclassified
TNFAIP1 201207_at ILMN_1655429 Tumor necrosis factor, alpha-induced
protein 1 (endothelial)
Molecular function unclassified Biologic process unclassified
TNS3 217853_at ILMN_1667893 Tensin 3 Protein phosphatase;
other phosphatase
Phospholipid metabolism; protein phosphorylation;
cell adhesion; immunity and defense;
induction of apoptosis; cell cycle control;
cell differentiation; tumor suppressor
WDYHV1 219060_at ILMN_1695491 Chromosome 8 open reading frame 32 Molecular function unclassified Biologic process unclassified
ZNF7 205089_at ILMN_1784281 Zinc finger protein 7 KRAB box transcription factor mRNA transcription regulation;
Cell proliferation and differentiation
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Supplementary Results
Predictive Performance of Published Gene Expression
Models in HNSCC Patients
We sought to determine whether two recently published predictive
models of radiation response in patients could predict outcome in our
data sets. We evaluated whether the Weichselbaum et al. [21] IFN-
related DNA damage resistance signature found to predict efficacy
of adjuvant chemo/radiotherapy in breast cancer patients was predic-
tive in our samples. We applied the IFN-related DNA damage resis-
tance signature model to the HNSCC data sets described previously,
and this did not successfully stratify patients according to response in
either ROC (Rickman data set; Wilcoxon rank-sum test, P = .5) or
Kaplan-Meier (evaluating multiple points on ROC as dichotomizing
cutoffs) analyses (Rickman data set; best overall survival Kaplan-Meier
χ2, P = .131; best progression-free survival Kaplan-Meier χ2, P = .258)
or multivariate Cox proportional hazards regression models (Rickman
data set; overall survival, P = .470; progression-free survival, P = .61).
The second model was one describing a 10-gene radiosensitivity in-
dex (RSI, high index = radioresistance) [22]. We evaluated this RSI
model on the BLA-40 and Rickman data sets. RSI was not significantly
Table W4. Cox Proportional Hazards Regression Model Analysis.
Coef Exp(Coef ) Se(Coef ) z P
(A) Cox proportional hazards regression model analysis for overall survival in the Rickman HNSCC patient data set (n = 72). AIC-based model selection.*
T stage 0.310 0.733 0.218 1.42 .160
N stage 0.700 2.013 0.422 1.66 .097
COXEN GEM score −0.989 0.372 0.497 −1.99 .047
(B) Cox proportional hazards regression model analysis for distant metastasis-free survival time in the Rickman HNSCC patient data set (n = 72). AIC-based model selection.†
COXEN GEM score −1.03 0.356 0.565 −1.83 .068
*Likelihood ratio test = 9.23 on 3 df, P = .0264, n = 72.
†Likelihood ratio test = 3.34 on 1 df, P = .0676, n = 72.
Figure W2. Characterization of the 41-gene GEM. (A) Pie chart representing the frequency of molecular function GO terms corresponding
to the genes in the 41-gene GEM. (B) Pie chart representing the frequency of biologic process GO terms corresponding to the genes in the
41-gene GEM. Normalized survival fractions for the BLA-40 cell line data set.
correlated with SF2 in the BLA-40 cell lines (Pearson correlation =
0.183, one-sided cor.test P = .132; Spearman correlation = 0.174,
one-sided cor.test P = .144). For the Rickman data set, RSI was not
significantly different between survivors and deceased or between
patients who relapsed and patients who did not relapse, for the entire
set of patients treated with radiation (with or without chemotherapy)
or for the set of patients treated with radiation alone.
Characteristics and Network Analysis
of the 41 Genes in the GEM
Genes corresponding to probes in the model were identified and GO
information obtained from the PANTHER database (Table W3). No
molecular function classification (FigureW1A) was found for 15 of the
41 genes, whereas no biologic process classification (Figure W1B) was
found for 16 of the 41 genes in the model. No GO terms are signifi-
cantly overrepresented among the genes for which such terms are avail-
able (hypergeometric test). However, biologic process terms that are
represented multiple times include immunity and defense (five genes),
transport (four genes), cell proliferation and differentiation (three
genes), and induction of apoptosis (three genes). Gene expression
and protein synthesis, activation, and destruction terms are also repre-
sented multiple times: mRNA transcription regulation (two genes),
protein biosynthesis (three genes), protein folding (two genes), protein
phosphorylation (three genes), and proteolysis (four genes). The most
common GO Biological Process classes were unclassified, transport,
immunity, and defense and proteolysis, whereas the GO Molecular
Function classes were unclassified, nucleic acid binding, ribosomal
proteins, and transcription factors.
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